Intestinal and circulating GUCA2B are decreased in experimental (19, 20, 29, 30) and human (25, 28, 31, 32) obesity, resulting in an impaired uroguanylin-GUCY2C endocrine axis in the obese state. Here, GUCA2B is linked to obesity disorder.